Salus Bio
Shenzhen, China· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
Overview
A Chinese developer of NGS sequencing platforms and spatial omics solutions for genomics research and precision diagnostics.
OncologyImmunology
Technology Platform
Proprietary next-generation sequencing (NGS) platforms (Saluseq series) and integrated spatial transcriptomics solutions, including specialized chips and reagent kits, for genomic and spatial omics analysis.
Opportunities
Growth is driven by domestic adoption of NMPA-approved clinical diagnostic sequencers (Salus Pro), expansion into the high-growth spatial biology market, and leveraging cost advantages in the competitive Chinese life science tools sector.
Risk Factors
Faces intense competition from well-capitalized global leaders (e.g., Illumina, MGI) and must continuously innovate; revenue depends on capital instrument sales and recurring consumable usage, which can be cyclical.
Competitive Landscape
Competes directly with MGI Tech (DNBSEQ platforms), Illumina (NovaSeq, NextSeq), and 10x Genomics (spatial omics) in China and Asia. Differentiation is sought through integrated spatial omics solutions, regulatory approvals for clinical use, and potentially lower cost of ownership.